Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Dactolisib (Primary) ; Everolimus
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms MACS1938
- Sponsors Novartis
- 25 Jan 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
- 09 Mar 2016 Status changed from completed to discontinued based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment, according to ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.